Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.
IPO Year:
Exchange: NASDAQ
Website: enochianbio.com
LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of Seraph Research Institute (SRI), presented data demonstrating daily reduction of Hepatitis B Virus (HBV) until it could no longer be detected by the 8th day. No toxicities to the liver or other tissues were identified. The findings were presented during the prestigious International Liver Conference, and presentations can be found (Link to presentations.) Enochian BioSciences holds the exclusive l
8-K - RENOVARO INC. (0001527728) (Filer)
10-Q - RENOVARO INC. (0001527728) (Filer)
8-K - RENOVARO INC. (0001527728) (Filer)
8-K - RENOVARO BIOSCIENCES INC. (0001527728) (Filer)
8-K - RENOVARO BIOSCIENCES INC. (0001527728) (Filer)
DEFA14A - RENOVARO BIOSCIENCES INC. (0001527728) (Filer)
8-K - RENOVARO BIOSCIENCES INC. (0001527728) (Filer)
8-K - RENOVARO BIOSCIENCES INC. (0001527728) (Filer)
DEFA14A - RENOVARO BIOSCIENCES INC. (0001527728) (Filer)
DEFM14A - RENOVARO BIOSCIENCES INC. (0001527728) (Filer)
LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company's Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies. "We are incredibly excited to bring on Dr. Whitley as a Senior Scientific Advisor," said Enochian's CEO Dr. Mark Dybul. "Rich is not only a talented clinician, but also a well noted researcher whose experience and expertise will be instrumental in
The Board learned of the arrest of Dr. Serhat Gumrukçu after the Press Release by the Department of Justice on May 25, 2022;The Board has verified that the incident leading to the arrest occurred prior to the merger which created the Enochian of today, and is completely unrelated to the Company;The Board reviewed the important scientific discoveries of the inventor and the Company's rights with regards to those discoveries, which will be unchangedThe Board confirmed that Dr. Serhat Gumrukçu has had no formal role in the Company, and has no involvement with the Company's strong management, scientific team and collaborations with leaders in the field;Therefore, the Board strongly affirms its c
LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ:ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, today is announcing the appointment of Dr. François Binette, Ph.D. as Executive Vice President for Research and Development. Dr. Binette brings over 25 years of Advanced Therapy and Regenerative Medicine product development expertise, most recently as Senior VP of Product Development at Lineage Cell Therapeutics where he led multiple innovative allogenic cell therapy programs from discovery to clinical stages and contributed to one of the largest non-cancer cell therapy corporate par
LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ:ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, announced today that Greg Duczynski is joining as Senior Vice President for Clinical Operations after a distinguished 32-year career with Pfizer. Since 2016, he has served as Senior Director, Clinical Development and Operations and Clinical Study Team Leader. He has been leading an international trial of gene therapy. During his time at Pfizer, Greg took on increasing levels of leadership across a broad range of functions within the Clinical Operations space including Clinical Project Management, Study
LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced the appointment of internationally renowned scientists and public health leaders to a Scientific Advisory Board (SAB) focused on potential inhaled treatment and prevention of any current or future variants of SARS-CoV-2 – the virus that causes COVID-19 – and Influenza. Dr. Peter Piot, KCMG, FRCP, FMedSci, Chairperson of the SAB, is the Handa Professor of Global Health, London School of Hygiene and Tropical Medicine, former founding Director of UNAIDS and co-discoverer of the Ebola virus. He is al
4 - RENOVARO INC. (0001527728) (Issuer)
3/A - RENOVARO INC. (0001527728) (Issuer)
4 - RENOVARO INC. (0001527728) (Issuer)
4 - RENOVARO INC. (0001527728) (Issuer)
4 - RENOVARO INC. (0001527728) (Issuer)
4 - RENOVARO BIOSCIENCES INC. (0001527728) (Issuer)
4 - RENOVARO BIOSCIENCES INC. (0001527728) (Issuer)
3 - RENOVARO BIOSCIENCES INC. (0001527728) (Issuer)
3 - RENOVARO BIOSCIENCES INC. (0001527728) (Issuer)
4 - RENOVARO BIOSCIENCES INC. (0001527728) (Issuer)
SC 13D/A - RENOVARO INC. (0001527728) (Subject)
SC 13D/A - RENOVARO INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancerIn silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary biomarker panelsRapidly expanding to other cancers and diseasesInnovative biotechnology firm with promising pancreatic cancer results projected to begin human studies for several challenging solid tumors by mid-2024Combination creates potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision, in silico drug discovery
Gainers Mallinckrodt (AMEX:MNK) stock rose 41.7% to $1.53 during Monday's regular session. Trading volume for this security as of 13:31 EST is 14.8 million, which is 377.2% of its average full-day volume over the last 100 days. The company's market cap stands at $20.1 million. GoodRx Holdings (NASDAQ:GDRX) stock moved upwards by 34.8% to $9.1. As of 13:31 EST, this security is trading at a volume of 17.8 million shares, making up 1432.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.6 billion. SmileDirectClub (NASDAQ:SDC) stock rose 22.42% to $0.86. SmileDirectClub's stock is trading at a volume of 8.0 million shares as of 13:
Gainers Dynatronics (NASDAQ:DYNT) stock moved upwards by 17.7% to $0.92 during Wednesday's after-market session. The market value of their outstanding shares is at $3.7 million. Novan (NASDAQ:NOVN) shares rose 9.99% to $0.2. Trading volume for this security closed at 4.6 million, accounting for 680.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.6 million. Trinity Biotech (NASDAQ:TRIB) shares moved upwards by 8.79% to $1.11. The company's market cap stands at $42.4 million. 9 Meters Biopharma (NASDAQ:NMTR) shares moved upwards by 8.32% to $0.18. 9 Meters Biopharma's trading volume hit 901.9K shares by close, accounting for 3
Gainers Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday. Healthcare Triangle, Inc. (NASDAQ:HCTI) shares gained 64.7% to $5.37 in pre-market trading after adding over 8% on Tuesday. FLJ Group Limited (NASDAQ:FLJ) shares rose 27.1% to $0.3661 in pre-market trading after declining around 5% on Tuesday. Enochian Biosciences Inc. (NASDAQ:ENOB) shares rose 26.4% to $0.6321 in pre-market trading. On July 7, 2023, Enochian Biosciences received a deficiency notice from the Nasdaq Stock Market informing the company that its common stock, par value $0.0001 per share, failed to comply with the $1 minimum bid price. Eloxx
Gainers CytoMed Therapeutics (NASDAQ:GDTC) stock moved upwards by 153.9% to $8.86 during Tuesday's pre-market session. The market value of their outstanding shares is at $102.1 million. Better Therapeutics (NASDAQ:BTTX) stock rose 35.55% to $1.22. The market value of their outstanding shares is at $38.7 million. Cingulate (NASDAQ:CING) stock rose 28.64% to $1.19. The market value of their outstanding shares is at $13.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 25.3% to $0.56. The company's market cap stands at $2.6 million. Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 18.63% to $0.24. The company's market cap stands at $7.1 million. Acumen Pharmaceuticals
Gainers PolyMet Mining Corp. (NYSE:PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share. Fresh Vine Wine, Inc. (NYSE:VINE) gained 70.1% to $0.3845. Fresh Vine Wine recently announced the appointment of Hitesh Dheri as Chief Financial Officer and Secretary. Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares jumped 65.1% to $6.32. Advanced Health Intelligence recently announced the implementation of an ADS ratio change. SQZ Biotechnologies Company (NYSE:SQZ) shares gained 46.1% to $0.3944 after declining 11% on Friday. IMAC Holdings, Inc. (NASDAQ:BACK) shares jumped 38.6% to $0.1524. Theralink rec
Gainers SQZ Biotechnologies (NYSE:SQZ) stock moved upwards by 58.5% to $0.43 during Monday's pre-market session. The market value of their outstanding shares is at $12.6 million. IMAC Hldgs (NASDAQ:BACK) stock rose 45.18% to $0.16. The company's market cap stands at $5.2 million. Ra Medical Systems (AMEX:RMED) stock rose 19.56% to $1.1. The company's market cap stands at $5.9 million. Myomo (AMEX:MYO) stock moved upwards by 17.65% to $0.61. The company's market cap stands at $12.7 million. Alvotech (NASDAQ:ALVO) stock increased by 14.98% to $8.9. The company's market cap stands at $2.3 billion. Comera Life Sciences (NASDAQ:CMRA) stock rose 14.17% to $0.56. The market value of their out
Gainers Baudax Bio (NASDAQ:BXRX) shares increased by 130.7% to $1.2 during Friday's regular session. Trading volume for this security as of 13:37 EST is 93.9 million, which is 10027.5% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million. CymaBay Therapeutics (NASDAQ:CBAY) stock increased by 41.61% to $11.1. The current volume of 13.9 million shares is 855.6% of CymaBay Therapeutics's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $1.0 billion. Renalytix (NASDAQ:RNLX) stock increased by 41.14% to $2.92. Trading volume for this security as of 13:37 EST is 29.7 m
-8-K
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary biomarker panels Rapidly expanding to other cancers and diseases Innovative biotechnology firm with promising pancreatic cancer results projected to begin human studies for several challenging solid tumors by mid-2024Combination creates potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision, in silico drug discovery LOS ANGELES, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQ:RENB) (NASDAQ:ENOB), an advanced, pre-clinical biot
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the "Annual Meeting"), which was scheduled to be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was convened and adjourned, without any business being conducted, due to the lack of the required quorum. As a result of the required quorum not being present, the Annual Meeting has been adjourned to 12:00 p.m. (Eastern Time) on Friday July 21, 2023 ("Adjourned Annual Meeting") to allow additional time for the Company's stockholders to vote on the
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company's Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024. The Company's proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. The important confirmatory results from two humanized mouse models using our novel dendritic-cell based therapy, indepen
LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB) -- Accelerated Pre-Investigational New Drug (Pre-IND) submission to the US Food and Drug Administration (FDA) for potential cancer product due to additional promising results from studies in a commonly used mouse modelDr. Anahid Jewett, a leading cancer researcher from the University of California, Los Angeles (UCLA) presented key results at the 8th Annual Innate Killer Summit last week (Link to presentation Excerpt)Pre-IND submission expanded to include a phase 1/2a safety and tolerability clinical study proposal for all solid tumors to be narrowed to 3-4 most promising indications during a later stage trial IND submission ta
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB). Enochian BioSciences Inc. (the "Company") announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (UCLA). The experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy with the Company's proprietary technology combining cell-, gene- and immunotherapy. Those results correlated with strong immune responses, indicating proof-of-concept of the way the technology was i
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively. "I am very pleased that the Company is once again compliant with the NASDAQ listing requirements. We have turned another page towards a promising future," said Gregg Alton, former long-time General Counsel and Chief Compliance Officer and, later, Interim CEO of Gilead Sciences, and Lead I
LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended December 31, 2022 (the "Form 10-Q"), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Co
LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2022 (the "Form 10-Q"), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously disclosed on Form 8-K filed with the Securities and Exchange Commission on October 21, 2022, on October 17, 2022, the Company previously
LOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world's deadliest diseases. Last week, the Company announced its oncology platform was awarded a U.S. patent and has produced promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also awaits potentially positive results from studies on its HIV platform, which are being conducted by scientists at the Fred Hutchinson Cancer Center. "We continue to prioritize the efficient research, development, and commercialization of our promising oncology and HIV pipeli
LOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) -- On October 17, 2022, Enochian BioSciences, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-K, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). This notification has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company's common stock will be subjec